PMID- 15629265
OWN - NLM
STAT- MEDLINE
DCOM- 20050603
LR  - 20191210
IS  - 1043-6618 (Print)
IS  - 1043-6618 (Linking)
VI  - 51
IP  - 2
DP  - 2005 Feb
TI  - 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is 
      mediated by endocannabinoid system.
PG  - 177-82
AB  - The appetitive potential of i.c.v. injections of 3,4 
      methylenedioxymethamphetamine (MDMA), using a conditioned place preference (CPP) 
      procedure, was investigated. In a range of doses (0.1-10 ng/rat), devoid of motor 
      stimulation, a dose-dependent CPP was obtained. The effect of the most effective 
      dose (10 ng/rat) was prevented by pre-treatment with the CB1 cannabinoid (SR 
      141716A) [N-piperidino-5-(4-chlorophenyl) 1-(2, 4-dichloro-phenyl)-4-methyl 
      pyrazole-3-carboxamide hydrochloride] (0.5 mg kg(-1)), the opioid (naloxone) (2 
      mg kg(-1)), and the serotonin 5-HT3, tropisetron [endo-8-methyl-8-azabicyclo 
      [3.2.1] oct-3-olindol-3-yl-carboxylate hydrochloride] (1 mg kg(-1)), receptor 
      antagonists, which did not induce place conditioning on their own. SR 141716A was 
      more efficient than naloxone and tropisetron in blocking the incentive learning 
      supported by MDMA. These results demonstrate for the first time that i.c.v. MDMA, 
      at very low doses, induces CPP and that endocannabinoid system may participate in 
      this effect.
FAU - Braida, D
AU  - Braida D
AD  - Department of Pharmacology, Chemotherapy and Medical Toxicology, Faculty of 
      Sciences, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.
FAU - Iosue, S
AU  - Iosue S
FAU - Pegorini, S
AU  - Pegorini S
FAU - Sala, M
AU  - Sala M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Cannabinoid Receptor Modulators)
RN  - 0 (Endocannabinoids)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazoles)
RN  - 0 (Receptor, Cannabinoid, CB1)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - RML78EN3XE (Rimonabant)
SB  - IM
MH  - Animals
MH  - Cannabinoid Receptor Modulators/*pharmacology
MH  - Conditioning, Psychological/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - *Endocannabinoids
MH  - Male
MH  - Motor Activity/physiology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Piperidines/*pharmacology
MH  - Pyrazoles/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Cannabinoid, CB1/antagonists & inhibitors/physiology
MH  - Rimonabant
EDAT- 2005/01/05 09:00
MHDA- 2005/06/04 09:00
CRDT- 2005/01/05 09:00
PHST- 2004/07/21 00:00 [accepted]
PHST- 2005/01/05 09:00 [pubmed]
PHST- 2005/06/04 09:00 [medline]
PHST- 2005/01/05 09:00 [entrez]
AID - S1043-6618(04)00191-4 [pii]
AID - 10.1016/j.phrs.2004.07.009 [doi]
PST - ppublish
SO  - Pharmacol Res. 2005 Feb;51(2):177-82. doi: 10.1016/j.phrs.2004.07.009.